Cue Biopharma (CUE) Change in Accured Expenses (2017 - 2025)

Cue Biopharma has disclosed Change in Accured Expenses across 9 years of filings, most recently posting -$259000.0 for Q4 2025.

• Change in Accured Expenses for Q4 2025 came in at -$259000.0, up 11.0% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.3 million (down 5.53% YoY), and the FY2025 annual result was -$1.3 million, down 5.53% from the prior year.
• Change in Accured Expenses came in at -$259000.0 for Q4 2025 at Cue Biopharma, down from $352000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.0 million in Q3 2021 to a low of -$2.7 million in Q2 2025.
• The 5-year median for Change in Accured Expenses is -$116000.0 (2021), against an average of -$58812.4.
• Across the five-year window, Change in Accured Expenses jumped 703.92% in 2023 and tumbled 320.47% in 2025, its largest moves.
• Cue Biopharma's Change in Accured Expenses stood at $630752.0 in 2021, then slumped by 152.32% to -$330000.0 in 2022, then sank by 198.48% to -$985000.0 in 2023, then jumped by 70.46% to -$291000.0 in 2024, then rose by 11.0% to -$259000.0 in 2025.
• The last three Change in Accured Expenses figures came in at -$259000.0 (Q4 2025), $352000.0 (Q3 2025), and -$2.7 million (Q2 2025), per Business Quant data.